Class / Patent application number | Description | Number of patent applications / Date published |
514212070 | Bicyclo ring system having the seven-membered hetero ring as one of the cyclos | 89 |
20080200450 | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction - Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction. | 08-21-2008 |
20080221082 | Ligands of Integrin Receptors - The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the α | 09-11-2008 |
20080227771 | Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A δd-crystalline form of ivabradine hydrochloride of formula (I): | 09-18-2008 |
20080242659 | COMPOSITIONS AND METHODS FOR REDUCING CARDIOVASCULAR MORBIDITY AND/OR MORTALITY - The present invention is related to a method for reducing cardiovascular morbidity and/or mortality comprising administering a combination comprising an ACE inhibitor and a CCB, specifically benazapril and amlodipine besylate. | 10-02-2008 |
20080269194 | Compositions And Methods Relating To Novel Compounds And Targets Thereof - The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, vascular abnormalities, and the like. | 10-30-2008 |
20080293691 | Treatment Method - The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed. | 11-27-2008 |
20090062256 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION - This invention relates to novel lactams having the Formula (I): | 03-05-2009 |
20090075976 | Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor - The present invention relates to the association of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also to pharmaceutical compositions containing them, and to methods of treating vascular complications associated with diabetes, with atherothrombotic diseases, with hyperlipidaemia, with hypertension, with chronic venous diseases, with inflammation, with metabolic syndrome associated with obesity, or with cancer, with such association. | 03-19-2009 |
20090099152 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME - The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide benzodiazepine compounds, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds, and to intermediate precursors to such compounds. | 04-16-2009 |
20090131404 | Combinations - The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) HMG-Co-A reductase inhibitors or a pharmaceutically acceptable salt thereof; and (ii) ACE inhibitors or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier. | 05-21-2009 |
20090137556 | COSMETIC AND PHARMACEUTICAL COMPOSITIONS COMPRISING ACE INHIBITORS AND/OR ANGIOTENSIN II RECEPTOR ANTAGONISTS - In one aspect, the present invention relates to use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of a dermatological disorder, particularly by topical application of said ACE inhibitor and/or angiotensin II receptor antagonist. The present invention also provides cosmetic methods for improving and/or maintaining the skin tone of an individual suffering from, or at risk of suffering from, a dermatological disorder, said method comprising contacting the skin of said individual with an ACE inhibitor and/or angiotensin II receptor antagonist. | 05-28-2009 |
20090156579 | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension - The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes-related disorders, hypertension, and hypertension-related disorders. | 06-18-2009 |
20090170831 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION - Field of the Invention This invention relates to novel lactams of Formula (I): | 07-02-2009 |
20090181946 | Benzaepinones as Sodium Channel Blockers - Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. | 07-16-2009 |
20090209515 | Association of a sinus node if current inhibitor and a Beta Blocker - Association of a sinus node If current inhibitor and a β-blocker and also pharmaceutical compositions containing it. | 08-20-2009 |
20090215745 | Association of a sinus node If current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it - Association comprising a selective and specific sinus node I | 08-27-2009 |
20090270367 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS - The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein. | 10-29-2009 |
20090281083 | Combination Product - There is provided a combination product comprising: (A) BH | 11-12-2009 |
20090318416 | Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A βd-Crystalline form of ivabradine hydrochloride of formula (I): | 12-24-2009 |
20090318417 | Gamma-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A γ-Crystalline form of ivabradine hydrochloride of formula (I): | 12-24-2009 |
20090318418 | Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A δd-crystalline form of ivabradine hydrochloride of formula (I): | 12-24-2009 |
20090318419 | Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A δ-crystalline form of ivabradine hydrochloride of formula (I): | 12-24-2009 |
20090318420 | Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - A γd-Crystalline form of ivabradine hydrochloride of formula (I): | 12-24-2009 |
20100009966 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION - This invention relates to novel lactams of Formula (I): | 01-14-2010 |
20100041640 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it - β-Crystalline form of ivabradine of formula (I): | 02-18-2010 |
20100137284 | Compositions for the Treatment and Prevention of Heart Disease and Methods of Using Same - The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease. This treatment is particularly effective in patients who have particularly heavy oxidative burdens, e.g. diabetics, patients with lung disorders, patients with sickle cell anemia and patients of Asian descent. | 06-03-2010 |
20100222326 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders - The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 09-02-2010 |
20100234350 | PLATELET ADP RECEPTOR INHIBITORS - Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof. | 09-16-2010 |
20100240636 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS - The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compounds. The compounds are useful as PPARγ agonist, through activating PPAR-RXR heterodimers that intereacts with specific DNA response elements within promoter regions of target gene, particularly in the treatment and prevention of polycystic kidney and cancer. | 09-23-2010 |
20100249103 | COMBINATION TREATMENT - A combination of a levosimendan compound or a pharmaceutically acceptable salt thereof and an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor shows synergistic effect in the prevention of stroke. Pharmaceutical compositions and medical kits comprising as a first active ingredient a levosimendan compound or a pharmaceutically acceptable salt thereof and as a second active ingredient an angiotensin II receptor antagonist or an angiotensin converting enzyme (ACE) inhibitor are provided. | 09-30-2010 |
20100267693 | Orodispersible pharmaceutical composition of ivabradine - The invention relates to a solid orodispersible pharmaceutical composition of ivabradine, characterised in that it comprises ivabradine or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch. | 10-21-2010 |
20100280005 | Renin Inhibitors - Disclosed are compounds of Formula I, wherein the R, R | 11-04-2010 |
20100298294 | KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS - The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease. | 11-25-2010 |
20100305099 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION - The present invention encompasses compounds of general formula (1) wherein A, B, R | 12-02-2010 |
20110009385 | COMPOUNDS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 01-13-2011 |
20110009386 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 01-13-2011 |
20110046113 | AMINE COMPOUND AND USE THEREOF - It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): | 02-24-2011 |
20110086844 | Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance - An immediate release pharmaceutical formulation of a poorly water-soluble biologically active substance with enhanced bio-availability, the formulation being a homogeneous and thermostable solid solution, and the solid solution including as percentages of the total weight of the formulation:
| 04-14-2011 |
20110105471 | NOVEL CRYSTALLINE COMPOUND AND A PROCESS FOR ITS PREPARATION - A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation. | 05-05-2011 |
20110105472 | Diaminopyrimidines as crop protection agents - Use of diaminopyrimidines of the formula (I) | 05-05-2011 |
20110118234 | Urea Compounds as Gamma Secretase Modulators - The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 05-19-2011 |
20110230466 | Association of a sinus node if current inhibitor and calcium inhibitor and pharmaceutical compositions containing it - Association comprising a selective and specific sinus node I | 09-22-2011 |
20110257158 | PRECOMPACTED FAST-DISINTEGRATING FORMULATIONS OF COMPOUNDS WITH A LOW ORAL BIOAVAILABILITY - This invention relates to the field of pharmaceutical chemistry. Embodiments of the present invention relate to, and provide precompacted fast-disintegrating formulations of compounds with a low oral bioavailability. | 10-20-2011 |
20110275614 | METHODS FOR THE PREPARATION OF IVABRADINE SULFATE AND FORM I CRYSTAL THEREOF - Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods thereof. | 11-10-2011 |
20110288072 | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction - Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl]-methyl }-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5 -tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction. | 11-24-2011 |
20110288073 | Alpha-Aminocyclolactam Ligands for G-protein Coupled Receptors, and Methods of Using Same - The invention relates to the generation of a library of compounds enriched in agonist and antagonists for members of the G-protein coupled class of receptors (GPCRs). | 11-24-2011 |
20110306596 | BENZAZEPINE INHIBITORS OF GAMMA-SECRETASE - The present invention relates to new benzazepine inhibitors of gamma-secretase activity, pharmaceutical compositions thereof, and methods of use thereof. | 12-15-2011 |
20110306597 | Nicotinamide Derivatives - The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions. | 12-15-2011 |
20110306598 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure - Use of the association of a selective and specific sinus node I | 12-15-2011 |
20120022044 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE - According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions. | 01-26-2012 |
20120122846 | FURO[3,2-d]PYRIMIDINE COMPOUNDS - The present invention is directed to novel compounds of Formula (I) | 05-17-2012 |
20120149688 | PLATELET ADP RECEPTOR INHIBITORS - Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof. | 06-14-2012 |
20120157444 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 06-21-2012 |
20120196850 | ASSOCIATION OF A SINUS NODE If CURRENT INHIBITOR AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Association comprising a selective and specific sinus node I | 08-02-2012 |
20120329780 | Novel kinase inhibitors - The present invention relates to novel compounds of formula (I) | 12-27-2012 |
20130040937 | INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES - The present invention relates to an I | 02-14-2013 |
20130090330 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | 04-11-2013 |
20130109672 | ACTIVATORS OF HUMAN PYRUVATE KINASE | 05-02-2013 |
20130116239 | IVABRADINE-CONTAINING PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE - The present invention relates to pharmaceutical compositions with delayed release which contain ivabradine adipate as active substance. The present invention furthermore relates to processes for the preparation of this composition and certain salts of ivabradine. | 05-09-2013 |
20130150345 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 06-13-2013 |
20130158008 | SOLID IVABRADINE-CONTAINING COMPOSITION - The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition. | 06-20-2013 |
20130178464 | DELTA CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, A PROCESS FOR ITS PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - Delta crystalline form of the compound of formula (I): | 07-11-2013 |
20130184256 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS - The present invention relates to new substituted glycinamides of general formula (I) | 07-18-2013 |
20130196977 | USE OF ORGANIC COMPOUNDS - The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with
| 08-01-2013 |
20130210805 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS - This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH | 08-15-2013 |
20130281438 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS - The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease. | 10-24-2013 |
20130317008 | Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure - The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment or prevention of heart failure of any aetiology. | 11-28-2013 |
20140038944 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 02-06-2014 |
20140051682 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 02-20-2014 |
20140100217 | STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE - The present invention provides a compound comprising a general formula 1: | 04-10-2014 |
20140155382 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 06-05-2014 |
20140171415 | FUNNY CURRENT (IF) INHIBITORS FOR USE IN A METHOD OF TREATING AND PREVENTING HEART DISEASE IN CANINE - The present invention relates to an I | 06-19-2014 |
20140179683 | SUSTAINED-RELEASE PREPARATION OF IVABRADINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - Disclosed is a sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof. The preparation contains ivabradine or pharmaceutically acceptable salts thereof and a sustained-release framework material, wherein the sustained-release framework material is selected from polyoxyethylene, or a mixture of polyoxyethylene and polyvinyl acetate or polyvinyl pyrrolidone. | 06-26-2014 |
20140221351 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 08-07-2014 |
20140221352 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. | 08-07-2014 |
20140275034 | Methods and Compositions Utilizing Lactams Derived from Camphor, Verbenone or Cat Thyme Oil for Repelling Blood-Sucking and Biting Insects, Ticks and Mites - A method for repelling blood-sucking and biting insects, ticks and mites involving treating an object or area with a blood-sucking and biting insects, ticks and mites repelling effective amount of camphor lactams, verbenone lactams, dolicholactams, dolicholactone, and their precursors, and mixtures thereof, and optionally a carrier. | 09-18-2014 |
20140315890 | IVABRADINE HYDROCHLORIDE FORM IV - Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation, and its use as therapeutically active ingredient. | 10-23-2014 |
20140323471 | POLYMORPHIC FORMS OF IVABRADINE HYDROCHLORIDE - Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed. | 10-30-2014 |
20140336179 | ACETONE SOLVATE OF IVABRADINE HYDROCHLORIDE - The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride. | 11-13-2014 |
20140364416 | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE - One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject. | 12-11-2014 |
20140364417 | METHOD OF TREATING ATRIAL FIBRILLATION - The present disclosure relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a therapeutically effective amount of ivabradine or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of ranolazine. Also provided are methods for modulating ventricular and atrial rate. This disclosure also relates to pharmaceutical formulations that are suitable for such combined administration. | 12-11-2014 |
20150025062 | HCN INHIBITORS AFFECTING GANGLION CELL FUNCTION AND VISUAL FUNCTION - The present invention is directed to a method of enhancing visual function in a subject, comprising administering to the subject in need of such enhancement, a therapeutically effective amount of an inhibitor of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the HCN channel inhibitor. | 01-22-2015 |
20150038491 | SOLID IVABRADINE-CONTAINING COMPOSITION - The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition. | 02-05-2015 |
20150148335 | LIQUID FORMULATION - The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension. | 05-28-2015 |
20150307515 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. | 10-29-2015 |
20150313872 | COMBINATION OF A SLOW SODIUM CURRENT BLOCKER AND A SINUS IF CURRENT INHIBITOR, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMBINATION - The present invention relates to the combination of a selective late sodium current blocker and a selective, specific sinus If current inhibitor, and to the pharmaceutical compositions containing said combination. | 11-05-2015 |
20150353499 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES - Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R | 12-10-2015 |
20160002176 | ERK INHIBITORS AND USES THEREOF - Compounds, compositions thereof, and methods for inhibiting one or both ERK1 and ERK2 kinases are provided. | 01-07-2016 |
20160113939 | Treating Patients with Compounds or Biological Agents That Pass the Safety Tests - The invention discloses a method of treatment for various severe disorders which is not treated well by current FDA approved drugs. The therapeutic agents by the method are compounds or biological agents which pass safety tests in the clinical trials, but not pass the efficacy test, as safety of those compounds or biological agents are comparable with any ones in the market which pass both safety and efficacy tests in the clinical trials, combined application of those compounds or biological agents can significantly improve varied severe medical conditions. | 04-28-2016 |